文献速递新生儿儿童神经与发育行为儿童内分泌与遗传代谢

预防性葡萄糖凝胶对新生儿低血糖及6至7岁神经认知功能的影响:随机临床试验二次分析

Prophylactic Dextrose Gel for Neonatal Hypoglycemia and Neurocognitive Function at 6 to 7 Years of Age: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2026-01-01

本研究为hPOD多中心双盲安慰剂对照试验的学龄期随访,纳入出生胎龄≥35周、体重≥2.2 kg且存在低血糖风险因素的新生儿,在生后1小时给予0.2 g/kg口腔葡萄糖凝胶或安慰剂。6至7岁时,两组神经认知损害比例相似(59% vs 57%;aRD 3%;95%CI -3%至9%;现有证据不支持常规使用葡萄糖凝胶预防新生儿过渡期低血糖。

要点

  • 预防性口腔葡萄糖凝胶未改善6至7岁神经认知损害风险。
  • 葡萄糖凝胶组情绪行为困难(24% vs 18%)和低心理社会功能(17% vs 12%)风险更高。
  • 现有证据不支持常规使用葡萄糖凝胶预防新生儿过渡期低血糖。

核心结论

  • 单剂葡萄糖凝胶预防低血糖对早学龄期神经认知损害风险影响很小至无影响,但可能对心理健康有不良影响。
  • 当前证据不支持常规使用葡萄糖凝胶预防新生儿过渡期低血糖。

研究设计与样本

  • 本研究为hPOD多中心、双盲、两臂平行、安慰剂对照随机临床试验的学龄期随访,在新西兰9家医院招募受试者。
  • 纳入胎龄≥35周、体重≥2.2 kg且具有至少1项过渡期低血糖风险因素(早产、母亲糖尿病、小于或大于胎龄、出生体重<2.5 kg或>4.5 kg)的儿童。
  • 干预为生后1小时给予0.2 g/kg口腔葡萄糖凝胶或安慰剂(羟甲基纤维素2%)。
  • 随访评估于2021年4月至2025年7月进行,主要在儿童学校完成;主要数据库提取于2025年7月24日,数据分析于2025年10月完成。

主要发现

  • 葡萄糖凝胶组532/652名(女性252名,男性280名,82%)和安慰剂组535/642名(女性271名,男性264名,83%)合格儿童完成评估。
  • 葡萄糖凝胶组较安慰剂组更易出现情绪行为困难(24% vs 18%;aRD 7%;95%CI 1%-12%)和低心理社会功能(17% vs 12%;aRD 6%;95%CI 1%-10%)。
  • 其他结局两组间相似。

关键数值与推荐

  • 主要结局为6至7岁时神经认知损害,定义为美国国立卫生研究院工具箱7项中至少1项标准分低于常模均值超过1个标准差。

临床怎么用

  • 对于有过渡期低血糖风险的晚期早产和足月儿,不应常规使用预防性口腔葡萄糖凝胶。
  • 临床决策需权衡葡萄糖凝胶对神经认知的潜在有限获益与情绪行为及心理社会功能的不良影响风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effective, safe, and infant-friendly interventions are needed to prevent transitional neonatal hypoglycemia, neonatal unit admissions, and neurological sequelae. OBJECTIVE: To determine if prophylactic buccal dextrose gel at 1 hour of age in at-risk late preterm and term infants improves neurocognitive function at 6 to 7 years of age, without adverse effects on general health and well-being. DESIGN, SETTING, AND PARTICIPANTS: This study focused on school-age follow-up of children in the Hypoglycaemia Prevention With Oral Dextrose (hPOD) multicenter, double-blind, 2-arm, parallel, placebo-controlled trial. Participants were recruited at birth across 9 hospitals in New Zealand. Follow-up was conducted primarily at the children's schools. Children in the hPOD Trial were born at 35 weeks' or more gestation and weighed 2.2 kg or more with 1 or more risk factors for transitional neonatal hypoglycemia: preterm, maternal diabetes, small or large for gestational age, or birth weight less than 2.5 kg or more than 4.5 kg. The assessments for this study (data collection) were performed from April 2021 to July 2025. The primary database extraction was on July 24, 2025. Data analysis was completed in October 2025. INTERVENTIONS: A 0.2-g/kg dose of buccal or placebo (hydroxymethylcellulose, 2%) at 1 hour of age. MAIN OUTCOME AND MEASURES: The primary outcome for this follow-up study was neurocognitive impairment at 6 to 7 years of age, defined as a standard score more than 1 SD below the normative mean on 1 or more of 7 items from the National Institutes of Health Toolbox. Eleven main exploratory outcomes included components of the primary outcome, low numeracy, visual perception, emotional-behavioral difficulty (Strengths and Difficulties Questionnaire), low physical or psychosocial functioning (Child Health Questionnaire), and overweight/obesity. RESULTS: There were 532 of 652 (252 female and 280 male [82%]) eligible children assessed in the dextrose gel group and 535 of 642 (271 female and 264 male [83%]) in the placebo group. The proportion with neurocognitive impairment was similar between groups (dextrose gel, 59%, vs placebo, 57%; adjusted risk difference [aRD], 3%; 95% CI, -3% to 9%; P = .36). Of exploratory outcomes, children who received dextrose gel, compared with placebo, were more likely to have emotional-behavioral difficulty (24% vs 18%; aRD, 7%; 95% CI, 1%-12%) and low psychosocial function (17% vs 12%; aRD, 6%; 95% CI, 1%-10%). Other outcomes were similar between groups. CONCLUSIONS AND RELEVANCE: In this follow-up study, a single dose of dextrose gel to prevent hypoglycemia, compared with placebo, had little to no effect on the risk of neurocognitive impairment at early school age, but could have adverse effects on psychological well-being. The current evidence does not support the routine use of dextrose gel for the prevention of neonatal transitional hypoglycemia. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Identifier: ACTRN12614001263684.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Harding JE, Alsweiler JM, Brown GTL, et al. Prophylactic Dextrose Gel for Neonatal Hypoglycemia and Neurocognitive Function at 6 to 7 Years of Age: A Secondary Analysis of a Randomized Clinical Trial. JAMA Pediatr. 2026. PMID: 42371617. doi:10.1001/jamapediatrics.2026.2486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。